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An expansion of glutamine repeats in the N-terminal domain of the huntingtin protein
leads to Huntington’s disease (HD), a neurodegenerative condition characterized by the
presence of involuntary movements, dementia, and psychiatric disturbances. Evaluation
of postmortem HD tissue indicates that the most prominent cell loss occurs in cerebral
cortex and striatum, forebrain regions in which cortical pyramidal neurons (CPNs) and
striatal medium spiny neurons (MSNs) are the most affected. Subsequent evidence
obtained from HD patients and especially from transgenic mouse models of HD indicates
that long before neuronal death, patterns of communication between CPNs and MSNs
become dysfunctional. In fact, electrophysiological signaling in transgenic HD mice is
altered even before the appearance of the HD behavioral phenotype, suggesting that
dysfunctional cortical input to the striatum sets the stage for the emergence of HD
neurological signs. Striatal MSNs, moreover, project back to cortex via multi-synaptic
connections, allowing for even further disruptions in cortical processing. An effective
therapeutic strategy for HD, therefore, may lie in understanding the synaptic mechanisms
by which it dysregulates the corticostriatal system. Here, we review literature evaluating
the molecular, morphological, and physiological alterations in the cerebral cortex, a key
component of brain circuitry controlling motor behavior, as they occur in both patients and
transgenic HD models.
Keywords: basal ganglia, glutamate transmission, huntingtin, neuronal processing
INTRODUCTION
In 1872, George Huntington described a disease that affects
certain families and is characterized by the presence of chor-
eic movements that gradually increase in severity and vari-
ety; his description led to the name Huntington’s disease (HD;
Huntington, 1872, 2003). Although Huntington described the
inherited feature of HD, it was not until 1983 that a DNA marker
linked to HD was identified at the tip of chromosome 4 (Gusella
et al., 1983). A decade later, in 1993, the same research group
reported that the HD mutation consists of an unstable CAG
repeat in exon 1 of the gene that codes for the protein called
“huntingtin” (HTT; HD Collaborative Research Group, 1993).
Normally, this exon contains between 3 and 30 CAGs, but if the
number of CAGs exceeds 35, HD becomes increasingly likely with
full penetrance occurring at ≥39 repeat (Harper, 2001). A rough
inverse correlation between the number of CAGs and the age of
HD onset occur (For review see, Langbehn et al., 2010). While
individuals carrying 40 CAG repeats are likely to show the first
signs of HD at 35–40 years of age; CAG repeats ranging from
50 to 200 (the highest number reported) may precipitate HD
onset in childhood or teenage years. The last is characterized with
psychiatric disturbances, accelerated mental and physical deteri-
oration that culminates in death as soon as 5–10 years after onset
(Rasmussen et al., 2000; Quarrell et al., 2012).
In adult-onset HD, patients show a progressive deteriora-
tion of motor and cognitive function that follows three well-
defined stages spread over 15–20 years (Harper, 1991). At the
initial stage and before the appearance of prominent motor alter-
ations, HD patients are likely to show psychiatric symptoms that
include apathy, irritability, depression, and other mood alter-
ations (Harper, 1991; Reedeker et al., 2012; Thompson et al.,
2012). Slight motor abnormalities, such as motor tics and jerky
voluntary movements, also are likely (Beste et al., 2009). The
second stage is characterized by a dramatic increase in involun-
tary movements, which become generalized, abrupt, and uncon-
trolled. As these choreic movements become more prominent,
daily activities such as walking, eating, speaking, and swallow-
ing deteriorate. In some cases, bradykinesia may coexist with
the choreic movements that become prominent in the third
stage (Thompson et al., 1988). Cognitive capacities progressively
decline and finally culminate in dementia. Another hallmark of
the second stage is the loss of body weight despite efforts to
maintain a high caloric diet (Marder et al., 2009). Overall health
progressively deteriorates and by the third stage, which typically
occurs 10–15 years after diagnosis. In this stage, choreic move-
ments are replaced by bradykinesia and rigidity. Death becomes
imminent, and the most common causes are pneumonia and
heart disease.
Soon after the HD gene was identified, different transgenic
animal models were developed. The models, together with stud-
ies performed on HD patients and on postmortem HD brains,
revealed that although mutant HTT is ubiquitously expressed,
the most prominent pathology occurs in cerebral cortex and
striatum. Cortical pyramidal neurons (CPNs) send massive and
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widespread projections to the striatum, forming the corticostri-
atal pathway that among other functions shapes motor behav-
ior. Because the development of involuntary movements is a
prominent feature of the HD phenotype, dysfunctional corti-
cal input to striatum is likely to constitute a key component
of HD neuropathology. In fact, emerging evidence from trans-
genic HD models suggests that the expression of mutant HTT
alters the pattern of communication between CPNs and medium
spiny neurons (MSNs) in the striatum. Striatal MSNs, more-
over, send information to downstream structures that project to
thalamus, which in turn projects back to cortex, allowing for
even further disruptions in cortical processing. Here, our aim
is to review the functional alterations in cerebral cortex in both
patients and transgenic models of HD and to assess how these
alterations disrupt the corticostriatal system to drive the HD
phenotype.
OVERVIEW OF CEREBRAL CORTEX ORGANIZATION
The cerebral cortex is the external sheet of neuronal tissue
that covers the entire brain. In mammals, cerebral cortex folds
together forming the “sulci” which compress a large portion
of cortical tissue in a small area. In humans the thickness of
the cerebral cortex is subject to regular local variations, but the
average values range from 1.5 to 4.5mm (Brodmann, 2010).
The cortical mantle is divided into specialized regions that con-
trol language, decision-making, and motor activity, among other
functions. Cortical neurons are organized into six main layers;
the most superficial lamina (Layer I) contains apical dendritic
tufts of CPNs and horizontal axons; it might also include the
so-called Cajal-Retzius and spiny stellate cells (von Economo,
1927). Layer II is composed of numerous small granule cells.
Layer III, contains large and robust CPNs, along with interneu-
rons (von Economo, 1927; Ichinohe, 2012). Layer IV, consists
of densely packed small polymorphous granule cells. Layer V,
contains large CPNs. Layer VI, contains large CPNs and small
spindle-like pyramidal and multiform neurons (von Economo,
1927). In addition to the different neuronal populations, astro-
cytes are homogeneously distributed throughout the six-layered
cortical organization (von Economo, 1927).
Cortical neurons make local connections between cells of dif-
ferent layers, also send and receive projections from other brain
regions (Szentágothai, 1975). For example, layer I in visual cortex
receives axonal ramifications from apical dendrites of pyramidal
neurons located in layers III and IV (Shipp, 2005, 2007). Layer
I also receives input from thalamic (matrix) M-type neurons
(Rubio-Garrido et al., 2009). Lateral connections occur between
neurons in layers II and III, but these neurons also send projec-
tions to layerV (Shipp, 2007). Neurons located in layer IV project
to layers II and III (Miller, 2003). In somatosensory cortex, pyra-
midal neurons in layer IV are the main target of thalamocortical
afferents from type (core) C-neurons (Jones and Pons, 1998).
CPNs from layer V are the principal source of input to the basal
ganglia, brain stem, and spinal cord. CPNs in layer VI send pro-
jections to thalamus (Shipp, 2007). Although similar intrinsic and
extrinsic connections are thought to occur along the length of the
cortical mantle, significant deviations occur among some func-
tionally distinct cortical areas. Detailed descriptions of cortical
connections are available elsewhere (Sherman and Guillery, 2011;
Espinosa and Stryker, 2012; Nieuwenhuys, 2012; Ray and Zald,
2012). In the next section, we focus on cortical motor areas and
their projections to basal ganglia.
MOTOR CORTEX AND ITS PROJECTIONS TO BASAL
GANGLIA
Motor cortex refers to the cortical areas associated with the plan-
ning, execution and control of voluntary movements. Motor
cortex is subdivided into multiple motor areas: primary motor
cortex (M1), premotor cortex dorsal caudal (PMdc), premo-
tor cortex dorsal rostral (PMdr), cingulate motor area caudal
(CGc), cingulate motor area rostral (CGr), premotor cortex ven-
tral caudal (PMvc), premotor cortex ventral rostral (PMvr), pre-
supplementarymotor area (Pre-SMA), and supplementarymotor
area (SMA; Schieber and Baker, 2003). These areas were identified
by evaluating motor responses elicited by electrical stimulation in
different species, including humans (Foerster, 1936; Penfield and
Boldrey, 1937; Bures and Bracha, 1990). Thus, motor areas are
localized to Brodmann’s cortical areas 4 (the giant pyramidal area)
and 6 (agranular frontal area) (Brodmann, 2010). Brodmann’s
areas 23 and 24 are now known to contain at least two addi-
tional motor areas (Schieber and Baker, 2003). Motor cortical
neurons follow the laminar organization, but motor cortex lacks
granular layer IV and layer III is relatively thinner (Brodmann,
2010). Motor cortex also is characterized by the presence of giant
pyramidal neurons known as Betz cells located in layer V; these
cells are the largest neurons in the brain, reaching dimensions
of 60–120/30–80µm: height/width (von Economo, 1927; Rivara
et al., 2003).
Motor cortical projections to the striatum, the first informa-
tion processing stage of the basal ganglia (Jinnai and Matsuda,
1979; McGeorge and Faull, 1989), arise mainly from layer V,
although retrograde labeling studies also identify pyramidal pro-
jections from layer III. Cortical projections are bilateral with
an ipsilateral predominance and release glutamate, an excita-
tory amino acid transmitter (McGeorge and Faull, 1989). Besides
motor cortical areas, the striatum receives projections form sen-
sory and associative cortical areas (Kemp and Powell, 1970).
Two types of striatal-projecting CPNs have been identified. They
can be distinguished by the morphology of their projection:
pyramidal tract (PT)-type neurons project to the striatum via col-
laterals arising from the main axon that extends to the PT and
intra-telencephalically projecting (IT)-type neurons that project
to striatum and cortex but not to areas outside telencephalon
(Lévesque et al., 1996; Reiner et al., 2003). Anatomical and func-
tional differences have been described between PT- and IT- type
neurons (For review see, Reiner et al., 2010). While the PT type
is mainly found in lower cortical layer V, the IT type is located
in layer III and upper layer V (Reiner et al., 2003; Parent and
Parent, 2006). Likewise, PT- and IT-type neurons differentially
target striatal MSNs such that IT-type neurons preferentially
target MSNs of the direct pathway and PT-type neurons prefer-
entially innervate MSNs of the indirect pathway (Lei et al., 2004;
Reiner et al., 2010). MSNs are GABAergic neurons that consti-
tute 95% of the neuronal population of the striatum and comprise
its main output system. Two MSN subtypes have been identified
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according to the proteins they express and their synaptic targets.
MSNs that preferentially express substance P, dynorphin, and the
D1-like dopamine receptor make up the direct pathway, which
projects to the internal segment of the globus pallidus (GPi)
and substantia nigra pars reticulata (SNr). The indirect pathway
is composed of MSNs that contain enkephalin and express the
D2-like dopamine receptor; these neurons project to the exter-
nal segment of the globus pallidus (GPe) and the subthalamic
nucleus, while also sending collaterals to GPi and SNr (Smith
et al., 1998).
Understanding the motor neuronal pathways involved in con-
trol, planning and execution of motor behavior is primary for
understanding neurophatologic conditions such as HD, in which
one of the main phenotypic alterations is the development of
involuntary movements.
CEREBRAL CORTEX IN HD: POSTMORTEM STUDIES
Postmortem evaluation of the human HD brain indicates a
30% reduction of total brain weight (De la Monte et al., 1988).
The most striking feature is neuronal loss in striatum (caudate-
putamen) along with enlarged lateral ventricles (De la Monte
et al., 1988). A scale of neuropathology based on the extent
of striatal atrophy has been developed (Vonsattel et al., 1985).
According to this scale, Grade 0 indicates that clinical symp-
toms are noticeable but with no observable neuropathological
alterations. Grade 1 is characterized by no macroscopic evidence
of damage but some neuronal loss and the presence of glio-
sis. Progressive striatal atrophy is observed in Grades 2 and 3,
which includes substantial reductions in the neuronal population
(>50%) and increased gliosis. Marked striatal atrophy (95% neu-
ronal loss) and widespread gliosis define Grade 4. In addition to
striatal damage, cortical changes also have been observed in post-
mortem studies of HD patients. Reduced cross-sectional area of
gray and white matter has been reported for frontal, temporal,
insular, and parietal cortical areas in HD Grades 2–4 (Mann et al.,
1993; Halliday et al., 1998). Likewise, De la Monte et al. (1988)
described a progressive reduction in overall cortical area and in
cortical white matter duringmild (Grades 1 and 2) and severe HD
(Grades 3 and 4). There also is evidence of reduced thickness of
the cortical ribbon (De la Monte et al., 1988; Heinsen et al., 1994).
These findings are consistent with a 30% reduction in the num-
ber of CPNs in cortical layer III, V and VI (Cudkowicz andKowall,
1990; Hedreen et al., 1991; Sotrel et al., 1991; Heinsen et al., 1994).
Moreover, primary motor cortex (Brodmann’s area 4) and the
premotor area (Brodmann’s area 6) of HD brains show a simi-
lar reduction in CPN numbers (Macdonald and Halliday, 2002;
Thu et al., 2010). Interestingly, the extent of cortical atrophy in
motor areas roughly correlates with the extent of the HD motor
phenotype (Halliday et al., 1998; Thu et al., 2010). It is equally
striking that in HD patients for whom mood alterations are the
primary symptom, the loss of CPNs is most prominent in cingu-
late cortex, which processes emotion (Thu et al., 2010). On the
other hand, despite progressive loss of CPNs, postmortem stud-
ies indicate that parvalbumin-, calretinin- and calbindin- positive
interneurons appear to be normally distributed without evident
morphological changes in motor cortical areas (Macdonald and
Halliday, 2002).
Together, these postmortem assessments indicate that corti-
cal atrophy and loss of CPNs is a neuropathological hallmark of
HD. Most of these studies, however, were performed on tissue
from neuropathological grades 2–4; little is known about cortical
atrophy at early HD stages and even before symptoms develop.
More importantly, a growing body of evidence from both HD
patients and transgenic models suggests that alterations in neu-
ronal communication precede neuronal loss and play a critical
role in the development of HD symptoms. Early support for this
view emerged from evaluation of proteins associated with synap-
tic transmission, including receptors, transporters, intra-cellular
signaling pathways, and vesicular neurotransmitter release (Cross
et al., 1986; Dunlop et al., 1992; Arzberger et al., 1997; Smith et al.,
2007; Hassel et al., 2008; Faideau et al., 2010). Subsequent support
has come from neuroimaging studies and recording of neuronal
activity (Miller and Bezprozvanny, 2010; Estrada-Sánchez and
Rebec, 2012; Hong et al., 2012c; Unschuld et al., 2012). The fol-
lowing sections focus on the cellular dysfunctions that are the
likely drivers of the HD behavioral phenotype.
FUNCTIONAL ALTERATIONS IN CEREBRAL CORTEX: HD
IMAGING STUDIES
Neuroimaging studies permit visualization of pathological
changes in vivo, before clinical symptoms develop. Techniques
such as magnetic resonance imaging (MRI), positron emis-
sion tomography (PET), and single-photon-emission computed
tomography (SPECT) have been used to detect brain atrophy
and functional changes in pre-symptomatic HD patients. These
approaches have not only confirmed the thinning of cerebral
cortex, but also showed that this effect occurs early, develops
progressively, and extends through the cortical mantle, although
distinct grades of cortical thinning may occur (Rosas et al., 2002,
2008, 2011). Interestingly, patterns of cortical thinning are associ-
ated with both the cognitive andmotor phenotypes. For example,
patients with more prominent bradykinesia and dystonia show
more significant thinning in premotor and supplementary motor
areas (Rosas et al., 2008). Moreover, longitudinal MRI evalua-
tions indicate that the progression and topological distribution
of cortical thinning is influenced by age of onset, suggesting an
important role of cerebral cortex in HD neuropathology (Rosas
et al., 2011).
Besides morphological changes, cerebral cortex also undergoes
several changes that might compromise neuronal communica-
tion. SPECT, a technique based on alterations in blood flow,
indicates reduced cerebral blood perfusion in presymptomatic
HD patients (Hasselbalch et al., 1992; Sax et al., 1996). Reduced
blood flow is widely observed along the cortical mantle and
precedes the presence of cortical atrophy as evaluated by MRI
(Jernigan et al., 1991; Hasselbalch et al., 1992; Sax et al., 1996).
Given that blood provides oxygen and glucose essential for brain
function, reduced blood perfusion in HD is likely to compromise
neuronal signaling mechanisms. Accordingly, reduced glucose
uptake and glucose metabolism have been identified in striatum
and cerebral cortex of pre-symptomatic HD patients, as studied
by 18F-fluorodeoxyglucose and PET (Kuhl et al., 1982; Kuwert
et al., 1989, 1990; Jenkins et al., 1998). The rate of glucose uptake
and its metabolism is an indicator of altered neuronal activity.
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Thus, these studies suggest altered cortical function before HD
symptoms become prominent, an effect that could alter com-
munication between CPNs and deep brain structures. In fact,
prodromal-HD patients show reduced corticostriatal functional
connectivity (Unschuld et al., 2012). Consistent with this view,
neuroimaging studies indicate white matter atrophy before the
onset of clinical symptoms (Fennema-Notestine et al., 2004;
Rosas et al., 2006, 2010). It appears, therefore, that compromised
cortical circuitry occurs early in the course of HD (Rosas et al.,
2006).
Collectively, these studies indicate that in HD the cerebral cor-
tex undergoes morphological and functional changes that occur
early in disease progression. Combined with evidence that the
cortical changes parallel the manifestation of both cognitive and
motor symptoms, these studies underscore the key role of cortical
neuropathology in HD. Neuroimaging studies, moreover, suggest
that cortical dysfunction rather than neuronal loss is a key factor
in HD onset. This hypothesis gained considerable support from
research on transgenic HD mice, which is reviewed in the next
sections.
TRANSGENIC HD MODELS
Transgenic mouse models of HD are often separated into three
broad categories based on the genetic manipulation: truncated,
full-length, and knock-in models. The truncated model expresses
only the first exon of the human mutant htt gene, while the full-
length model expresses the entire human mutant htt gene. Thus,
these two models express two normal alleles of the endogenous
Hdh gene (the murine analog of htt) along with all or part of the
exogenous human htt gene. In the knock-in model, CAG repeats
are “knocked in” or directly inserted into the first exon of the
endogenous Hdh gene.
Truncated models were developed first, and are represented
by the R6 line of mice. Two variants are available: the R6/1 line,
which contains ∼110 CAG repeats, and the R6/2 line, which con-
tains ∼150 CAG repeats (Mangiarini et al., 1996). More recently,
other truncated models have been created, including the N171-
82Q mouse that expresses cDNA encoding 171 amino acids in
the first exon of the htt gene with 82 CAG repeats (Schilling
et al., 1999). A truncated transgenic HD rat model with 51 CAG
repeats also has been created (von Hörsten et al., 2003). Like
the truncated R6 line, the full-length HD model has two vari-
ants: the yeast artificial chromosome (YAC) and the bacterial
artificial chromosome (BAC) models, the names of which refer
to the genetic tool (yeast or bacteria) used to insert the human
mutant htt gene. Three different YAC models are available based
on CAG-repeat length, YAC46, YAC72, and YAC128; the latter
is the most widely studied of this group (Hodgson et al., 1999).
The BAC model expresses 97 CAG repeats (Gray et al., 2008).
Finally, several knock-in variants have been developed, includ-
ing: Hdh/Q72-80, Hdh Q111, CAG140, and CAG150 models,
again with the numbers indicating CAG-repeat length (Menalled,
2005).
Despite the genetic difference that exists among HD trans-
genic models, they all develop a form of the behavioral phenotype
and neuropathology seen in patients. HD transgenic models how-
ever, show varying degrees of behavior and neuropathological
alterations. Truncated R6 models, for example, develop accel-
erated progressive motor alterations, reduced body weight, and
shortened lifespan (∼10–14 and 3–5 months for R6/1 and R6/2,
respectively) (Mangiarini et al., 1996). At the neuropathological
level, these models show intracellular and intranuclear aggregates
containing themutantHTT fragment and other proteins; reduced
striatal volume and neuronal atrophy also occur (Mangiarini
et al., 1996; Davies et al., 1997; Stack et al., 2005). The N171-82Q
model also has decreased body weight and motor alterations, but
these are less severe than in the R6/2 model (Kim et al., 2011).
The neuropathological changes, however, are similar to those
described in the R6 models (Yu et al., 2003; McBride et al., 2006;
Kim et al., 2011). In the case of the truncated HD transgenic rat,
there are intracellular aggregates, but unlike the truncated mouse
model, neurological deficits emerge in adulthood along with pro-
gressive motor alterations (von Hörsten et al., 2003). Full length
models, on the other hand, show important differences relative to
truncated models. For example, a notable increase in body weight
occurs in the BACHD andYAC128models (Van Raamsdonk et al.,
2006; Pouladi et al., 2010, 2012). Both also show reduced stri-
atal volume, although the presence of intracellular aggregates is
more prominent in the striatum of YAC128 models (Gray et al.,
2008; Spampanato et al., 2008; Miller et al., 2011b; Pouladi et al.,
2012). Although full length models show impaired performance
in motor tests, the motor changes are relatively mild compared
with truncated models (Ferrante, 2009; Kim et al., 2011). Similar
to full length models, knockin HD mice show slowly emerging
motor changes along with intracellular aggregates and striatal
atrophy (For review see, Menalled, 2005). Interestingly, the neu-
ropathology in aged knockin mice (21 months of age) resembles
that described for R6/2 mice, including widespread expression
of aggregates and transcriptional alterations (Woodman et al.,
2007).
These findings indicate important differences in the neural
and behavioral phenotypes among the HD models. However, it
is important to note that despite these differences, behavioral
alterations appear prior to neuronal loss, suggesting that HD
neurological signs are likely to be caused by impaired neuronal
communication, particularly in the corticostriatal pathway.
DYSFUNCTIONAL CORTICOSTRIATAL NETWORK IN HD;
EVIDENCE FROM TRANSGENIC MODELS
Electrophysiological recordings of CPNs in truncated and full
length HD models indicate a change in electrical properties
such as resting membrane potential, input resistance, and cell
capacitance (Cummings et al., 2006, 2009). Similar membrane
changes were observed in vivo during intracellular recordings
of R6/2 CPNs (Stern, 2011). Likewise, there is consistent evi-
dence of an imbalance between excitatory and inhibitory inputs
to CPNs in HD, which may underlie hyperexcitable cortical neu-
rons reported for HD models (Gu et al., 2005; Spampanato et al.,
2008; Cummings et al., 2009).
Impaired CPN activity in HD also is likely to interfere
with synaptic plasticity. Progressive alterations in long-term
depression (LTD) occur in the perirhinal cortex of R6/1 mice
(Cummings et al., 2006, 2007). Similarly, CPNs in medial
prefrontal cortex show impaired long-term potentiation (LTP)
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(Dallérac et al., 2011). Interestingly, in both cases, the loss of
synaptic plasticity can be reversed by the activation of dopamine
receptors (Cummings et al., 2006, 2007; Dallérac et al., 2011),
suggesting an HD-induced change in dopamine modulation
of cortical processing. This change may underlie the defi-
cient cortical plasticity observed in R6/1 model performance
in a somatosensory-discrimination learning task (Cybulska-
Klosowicz et al., 2004; Mazarakis et al., 2005).
Dysfunctional interneurons also may contribute to impaired
CPN activity in HD. For example, reduced GABAergic inhibitory
input from interneurons occurs in HD models (Gu et al., 2005;
Cummings et al., 2009). In BACHD mice at 3 months of age—
when the motor phenotype is relatively mild—parvalbumin-
containing interneurons in layers II and III show alterations in
the kinetics of decay of spontaneously occurring inhibitory and
excitatory postsynaptic currents (sIPSC and sEPSC, respectively;
Spampanato et al., 2008). At 6 months, when motor alterations
are more prominent, parvalbumin-containing interneurons show
decreased excitation, while CPNs show decreased inhibition, indi-
cating increased cortical excitability (Spampanato et al., 2008).
Thus, cortical interneurons and CPNs show alterations that par-
allel the progressive motor phenotype seen in the BACHDmodel.
Moreover, these results also suggest that interneurons might have
an important role in the HD phenotype, given that their alter-
ations may precede CPN dysfunction. In line with this view, it
has been suggested that inhibitory interneurons are involved in
shaping motor commands (For review see, Merchant et al., 2012).
Neurons communicate through the modulation of firing rate
and by the generation of spike bursts, which are epochs of high fir-
ing frequency. Burst firing is relevant for the efficiency of neuronal
transmission and also plays a role in neuronal plasticity (Lisman,
1997; Izhikevich et al., 2003). Cortical activity recorded in freely
behaving R6/2 mice is characterized by decreased bursting activ-
ity and a decrease in the number of spikes that participate in
a burst (Walker et al., 2008). Similarly, reduced bursting occurs
in cultured cortical neurons expressing a fragment of mutant
HTT (Gambazzi et al., 2010). Cortical neurons in both R6/2
and Hdh CAG140 mice are more likely to show a decrease in
correlated activity between simultaneously recorded pairs of neu-
rons than corresponding wild-type controls (Walker et al., 2008).
Consistent with this evidence, in vivo intracellular recordings in
HD mice indicate a decreased correlation between cortical spik-
ing and simultaneously recorded electrocorticograms relative to
wild-type (Stern, 2011). Importantly, correlated neuronal activity
is a key factor in the operation of the neuronal circuits that shape
behavior (Berke et al., 2004; Buzsáki and Chrobak, 2005; Burns
et al., 2010), suggesting that deficient synchronous activity in cor-
tical HD neurons is associated with the behavioral alterations in
HD transgenic models (Walker et al., 2011). Interestingly, local
field potentials (LFPs), which represent the activity of large pop-
ulations of neurons in the vicinity of the recording electrode, also
are altered in cortex of HDmice (Hong et al., 2012c). In this case,
however, LFPs show the greatest deviation from wild-type dur-
ing quiet rest and less so as behavior switches to grooming and
exploring. It may be that the high frequency oscillations (∼32Hz)
in resting HD mice prompt motor activation. In fact, HD mice
spend less time resting than wild-type (Hong et al., 2012c).
Along with alterations in CPNs activity, striatal MSNs also
show altered electrophysiological properties (reviewed by Cepeda
et al., 2007). When studied in vitro, MSNs show increased
excitability as indicated by a depolarized resting membrane
potential and enhanced sensitivity to ionotropic glutamate recep-
tor activation (Hodgson et al., 1999; Levine et al., 1999; Cepeda
et al., 2001; Klapstein et al., 2001; Laforet et al., 2001; Milnerwood
and Raymond, 2007). This evidence is consistent with increased
firing in striatal MSNs recorded from behaving, symptomatic
R6/2 mice (Rebec et al., 2006). As in cortex, decreased MSN
bursting activity is the most common electrophysiological fea-
ture reported for HD models (Miller et al., 2008b, 2010, 2011a;
Cayzac et al., 2011). As in CPNs, reductions in correlated fir-
ing and coincident bursting between simultaneously recorded
pairs of MSNs occur in HD striatum (Miller et al., 2008b, 2010,
2011a; Höhn et al., 2011). In addition, striatal LFPs in behav-
ing R6/2s parallel cortical LFPs in that high frequency gamma
activity (focused around 32Hz) predominates during quiet rest
(Hong et al., 2012a,b). Interestingly, LFP oscillations recorded in
the globus pallidus of HD patients show alterations in theta/alpha
(4–12Hz) and low gamma (35–45) activity (Groiss et al., 2011).
Collectively, these studies indicate that altered neuronal pro-
cessing occurs in cerebral cortex of HD transgenic models, indi-
cating that CPNs send aberrant information to MSNs. In fact,
analysis of simultaneous recordings of LFPs from primary motor
cortex and dorsal striatum, which receives major motor cortical
input, indicates an overall reduction in the level of coherence or
synchrony between these brain regions in R6/2 relative to wild-
type mice across a range of behavioral episodes (Hong et al.,
2012c). Given that dysfunctional corticostriatal processing occurs
before HD signs are noticeable, these results provide further sup-
port for the hypothesis that altered neuronal communication is a
prerequisite for the HD behavioral phenotype.
MECHANISM INVOLVED IN DISRUPTED CORTICOSTRIATAL
COMMUNICATION IN HD
A critical question is how mutant HTT alters corticostriatal
neuronal activity. Two mechanisms have been suggested: cell-
autonomous toxicity and cell–cell interaction toxicity (Gu et al.,
2005, 2007). The first proposes that the expression of mutant
HTT itself is enough to alter the key neuronal mechanisms
that lead to neuronal dysfunction. In support of this mecha-
nism, in vitro and in vivo studies indicate that mutant HTT
disrupts gene expression, calcium buffering, and mitochondrial
function (Choo et al., 2004; Milakovic and Johnson, 2005; Tang
et al., 2005; Thomas et al., 2011). The second mechanism pro-
poses that the interaction between different cell populations is
critical for the development of HD. Support for this hypothe-
sis includes altered release of brain derived neurotrophic factor
(BDNF) from corticostriatal synapses (reviewed by Zuccato and
Cattaneo, 2009), impaired glutamate release from cortical pro-
jections (Cepeda et al., 2001; Klapstein et al., 2001; Laforet
et al., 2001; Milnerwood and Raymond, 2007), and disrupted
glutamate uptake by the astrocytes (Nicniocaill et al., 2001;
Hassel et al., 2008). Collectively, these studies indicate that both
cell-autonomous and cell–cell interaction toxicity are likely to
occur in HD. Thus, a combination of both mechanisms may
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disrupt neuronal communication and promote development of
the HD phenotype.
Impaired energy production appears to be a key alteration
in HD, as both HD transgenic models and HD patients show
alteration in glycolytic and mitochondrial activity (Browne and
Beal, 2004; Powers et al., 2007; Verwaest et al., 2011; Cepeda-
Prado et al., 2012). Because neurons are highly dependent on ATP
production, decreased glucose metabolism may compromise the
activity of Na+/K+ ATPase, a key protein that helps to maintain
the ionic gradient across the neuronalmembrane (Bonvento et al.,
2002). If the gradient is not maintained by this protein, neurons
become depolarized and more excitable, which may explain evi-
dence for increased neuronal excitability in transgenic HDmodels
(see above). Deficient energy production and a loss of the ionic
gradient, moreover, may compromise the function of glutamate
transporters, transmembrane proteins located in neurons and
astrocytes. These transporter proteins depend on the Na+ gra-
dient generated by the Na+/K+ ATPase to ensure glutamate clear-
ance from the synapse and extracellular space. It is noteworthy
that decreased glutamate uptake, a well-described feature of HD
(Nicniocaill et al., 2001; Hassel et al., 2008; Miller et al., 2008a;
for review see Estrada-Sánchez and Rebec, 2012), may result, at
least in part, from decreased energy production. In this sense,
glycolytic inhibition reduced glutamate transporters levels in the
striatum of R6/2 model (Estrada-Sánchez et al., 2010). Moreover,
compromised glutamate uptake coupled with impaired cellular
metabolism may render neurons vulnerable to excitotoxic dam-
age, a mechanism involved with neurodegeneration of MSNs in
HD (Estrada-Sánchez et al., 2008, 2009, 2010). Besides, impaired
function of glutamate transporters at corticostriatal synapses
might compromise the dynamic of synaptic transmission, leading
to aberrant neuronal processing (Beurrier et al., 2009). These
mechanisms, of course, are likely to occur in conjunction with
many other contributing factors, including altered expression and
function of synaptic receptors, increased production of reactive
oxidative species, diminished neuronal antioxidant capabilities
(For reviews of these and other likely factors see: Browne et al.,
1997; André et al., 2006; Chen, 2011; Kaplan and Stockwell,
2012).
CONCLUSION
An emerging picture of HD neuropathology includes aberrant
cortical signaling that impacts striatal output systems and that
then affects thalamic input back to cortex. In short, HD is char-
acterized by dysregulated information flow through the cortico-
striato-cortical pathway. This problem, moreover, emerges early
in the course of HD, even before some neurological signs are
present, suggesting a key role in the development and subsequent
progression of the HD behavioral phenotype. Further research on
alterations in cortical processing in HD, including the contribu-
tion of thalamic inputs and cortical interneurons, is emerging as
fertile ground for further insight into the neuronal mechanisms
underlying HD and for the development of effective therapeutic
strategies.
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